<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505723</url>
  </required_header>
  <id_info>
    <org_study_id>2018.02.16</org_study_id>
    <nct_id>NCT03505723</nct_id>
  </id_info>
  <brief_title>PeriOperative ISchemic Evaluation-3 Trial</brief_title>
  <acronym>POISE-3</acronym>
  <official_title>PeriOperative ISchemic Evaluation-3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, international, randomized controlled trial of tranexamic acid
      (TXA) versus placebo and, using a partial factorial design, of a perioperative
      hypotension-avoidance versus hypertension-avoidance strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The POISE-3 study is a 10,000 patient, multicentre, international, non-inferiority randomized
      controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial
      design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The
      primary objective of the study is to determine; if TXA is superior to placebo for the
      occurrence of life-threatening, major, and critical organ bleeding, and non-inferior to
      placebo for the occurrence of major arterial and venous thrombotic event; and to determine
      the impact of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on
      the risk of vascular death and major vascular events in patients who are followed for 30 days
      after noncardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of life-threatening bleeding, major bleeding, and critical organ bleeding</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who have at least one of the following: life-threatening bleeding, major bleeding, and critical organ bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>A composite of myocardial infarction, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism.</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who have at least one of the following: myocardial infarction, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For patients in the blood pressure management arm: A composite of vascular death, and non-fatal myocardial infarction, stroke, and cardiac arrest.</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients enrolled in the blood pressure management arm who have at least one of the following: vascular death, and non-fatal myocardial infarction, stroke, and cardiac arrest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A net risk-benefit outcome as a composite of vascular death, and non-fatal life-threatening, major or critical organ bleeding, MI, stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism.</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who have at least one of the following: vascular death, and non-fatal life-threatening, major or critical organ bleeding, myocardial infarction, stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Society on Thrombosis and Haemostasis (ISTH) major bleeding</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience major bleeding (as defined by ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIMS</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience bleeding impacting mortality after noncardiac surgery (BIMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MINS</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a myocardial injury after noncardiac surgery (MINS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients in the blood pressure management arm: all-cause mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who die of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients in the blood pressure management arm: MINS</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a myocardial injury after noncardiac surgery (MINS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients in the blood pressure management arm: Myocardial infarction</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a myocardial infarction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Life threatening bleeding</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a life threatening bleed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a major bleed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Critical organ bleeding</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience bleeding in a critical organ.</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-hemorrhagic stroke</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a non-hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral arterial thrombosis</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience peripheral arterial thrombosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic proximal venous thromboembolism</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a symptomatic proximal venous thromboembolism</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who die of any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Vascular mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who die of vascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Transfusion rate</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Rate of transfusion in patients who experience a major bleeding event</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac revascularization</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who have undergo cardiac revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>Amputation</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who have an amputation</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic pulmonary embolism</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a symptomatic pulmonary embolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic proximal DVT</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a symptomatic proximal DVT</description>
  </other_outcome>
  <other_outcome>
    <measure>Any symptomatic or asymptomatic proximal venous thromboembolism</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience any (symptomatic or asymptomatic) proximal venous thromboembolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience an acute kidney injury</description>
  </other_outcome>
  <other_outcome>
    <measure>New renal replacement therapy</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who require new renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-hospitalization for vascular reasons</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a re-hospitalization for vascular reasons</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizures</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a seizure</description>
  </other_outcome>
  <other_outcome>
    <measure>Infection/sepsis</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience infection/sepsis</description>
  </other_outcome>
  <other_outcome>
    <measure>Disability</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]).</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Average length of hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: vascular death</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who die from a vascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: non-fatal myocardial infarction</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a non-fatal myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: stroke</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: cardiac arrest</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience cardiac arrest</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: hemorrhagic stroke</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: non-hemorrhagic stroke</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a non-hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: acute kidney injury</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience an acute kidney injury</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: new renal replacement therapy</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients with new requirement for renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: acute congestive heart failure</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience acute congestive heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: new onset atrial fibrillation</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience new onset of atrial fibrillation</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: sepsis</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience a sepsis event</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: disability</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]).</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: cancellation/postponement of surgery on the day of surgery due to BP concerns</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Number of patients whose surgery was cancelled/postponed on the day of surgery due to BP concerns</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: length of hospital stay</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Average length of hospital stay required</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who die of any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Vascular mortality</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who die of vascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrest</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience cardiac arrest</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-hemorrhagic stroke</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a non-hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral arterial thrombosis</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience peripheral arterial thrombosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Amputation</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who had an amputation</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic pulmonary embolism</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a symptomatic pulmonary embolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic proximal DVT</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a symptomatic proximal DVT</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptomatic proximal venous thromboembolism</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a symptomatic proximal venous thromboembolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Any symptomatic or asymptomatic proximal venous thromboembolism</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience any symptomatic or asymptomatic proximal venous thromboembolism</description>
  </other_outcome>
  <other_outcome>
    <measure>New renal replacement therapy</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who require new renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-hospitalization for vascular reasons</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients re-hospitalized for vascular reasons</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizures</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a seizure</description>
  </other_outcome>
  <other_outcome>
    <measure>Infection/sepsis</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience an infection and/or sepsis event</description>
  </other_outcome>
  <other_outcome>
    <measure>Disability</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]).</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: all-cause mortality</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who die of any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: vascular mortality</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who die of a vascular cause</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: myocardial infarction</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: cardiac arrest</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience cardiac arrest</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: hemorrhagic stroke</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: non-hemorrhagic stroke</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a non-hemorrhagic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: new renal replacement therapy</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who require new renal replacement therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: acute congestive heart failure</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience acute congestive heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm: sepsis</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience a sepsis event</description>
  </other_outcome>
  <other_outcome>
    <measure>For patients in the blood pressure management arm:</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Perioperative Bleeding</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Arterial Thrombosis</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.9% normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotension-avoidance strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perioperative hypertension-avoidance strategy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.</description>
    <arm_group_label>Tranexamic Acid (TXA)</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Saline)</intervention_name>
    <description>Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.</description>
    <arm_group_label>Placebo (0.9% normal saline)</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Perioperative hypotension-avoidance strategy</intervention_name>
    <description>Perioperative hypotension-avoidance strategy includes:
Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,
Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg
Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery.</description>
    <arm_group_label>Hypotension-avoidance strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Perioperative hypertension-avoidance strategy</intervention_name>
    <description>Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.</description>
    <arm_group_label>Perioperative hypertension-avoidance strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Undergoing noncardiac surgery;

          2. ≥ 45 years of age;

          3. Expected to require at least an overnight hospital admission after surgery;

          4. Provide written informed consent to participate in the POISE-3 Trial, AND

          5. Fulfill ≥1 of the following 6 criteria (A-F):

        A. NT-proBNP ≥200 ng/L B. History of coronary artery disease C. History of peripheral
        arterial disease D. History of stroke E. Undergoing major vascular surgery; OR F. Any 3 of
        9 risk criteria i. Undergoing major surgery; ii. History of congestive heart failure; iii.
        History of a transient ischemic attack; iv. Diabetes and currently taking an oral
        hypoglycemic agent or insulin; v. Age &gt;70 years; vi. History of hypertension; vii. Serum
        creatinine &gt; 175 µmol/L (&gt; 2.0 mg/dl); viii. History of smoking within 2 years of surgery;
        ix. Undergoing emergent/urgent surgery.

        Exclusion criteria:

          1. Planned use of systemic TXA during surgery

          2. Hypersensitivity or known allergy to TXA

          3. Creatinine clearance &lt;30 mL/min (Modification of Diet in Renal Disease [MDRD])

          4. History of seizure disorder

          5. Patients with recent stroke, myocardial infarction, acute arterial thrombosis or
             venous thromboembolism (&lt;1 month)

          6. Patients with subarachnoid hemorrhage within the past 30 days

          7. Patients undergoing cranial neurosurgery

          8. Previously enrolled in POISE-3 Trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PJ Devereaux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Vincent, MSc</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40635</phone_ext>
    <email>Jessica.Vincent@phri.ca</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>P.J. Devereaux</investigator_full_name>
    <investigator_title>Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Noncardiac surgery</keyword>
  <keyword>Myocardial injury</keyword>
  <keyword>Perioperative myocardial infarction</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

